CRISPR gene-editing technology is displaying promising potential for the treatment of neurodegenerative diseases, such as Alzheimer’s, Parkinson’s and Huntington’s. Despite neurodegenerative diseases being difficult to treat due to their complexity, early-stage research using CRISPR to edit genes linked to these diseases is proving successful. However, full understanding of these diseases is still lacking, and barriers like effective delivery of treatment and understanding of long-term safety need to be overcome.
Group-IB’s Threat Intelligence and Defence Centre Equip Undergraduates with Sophisticated Cybersecurity Technologies to Boost Threat Analysis and Enhance Cyber Resilience for Campus Start-ups
Hey there from the heart of the San Francisco Bay Area! It’s an absolute pleasure to have you back again for our chat on some
